RxDoctor Payments Data

Summer Wilcox

Family · Fort Mohave, AZNPI 1427307941

Payments from drug & device makers

$339in general payments, 2019–2025

Across 18 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$79
  • Verona Pharma, Inc.$63
  • Biohaven Pharmaceuticals, Inc.$61
  • Lilly USA, LLC$30
  • Pfizer$30
  • Bioventus LLC$25
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$339 in reported general payments places this provider in the 50th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$87,034
Medicare patients
259
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$95,706
OzempicSemaglutide84$90,181
Cimzia (2 Pack)Certolizumab Pegol12$68,184
XareltoRivaroxaban51$65,744
MounjaroTirzepatide37$42,415
JardianceEmpagliflozin32$41,118
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$26,447
Combivent RespimatIpratropium/Albuterol Sulfate31$25,302
JanuviaSitagliptin Phosphate15$23,647
Tresiba Flextouch U-200Insulin Degludec13$21,527
Breo ElliptaFluticasone/Vilanterol36$19,602
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$15,924
LinzessLinaclotide13$14,917
Spiriva RespimatTiotropium Bromide11$11,653
Albuterol Sulfate HfaAlbuterol Sulfate274$11,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$95,70662 claims
Novo NordiskOzempic$20$90,18184 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$16$51,35980 claims
Lilly USA, LLCMounjaro$30$42,41537 claims
MerckJanuvia$79$23,64715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,119 family providers in Arizona.

Other family in Fort Mohave

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →